肝药酶基因多态性及其对镇痛麻醉药品的影响  

Gene Polymorphism of Cytochrome P450 and Its Influence on Anesthetic and Analgesic Drugs

作　　者：于景娴[1] 池里群[1] 秦红梅[1] 鄂文[2] 

机构地区：[1]北京市海淀区妇幼保健院,北京100080 [2]北京大学医学部病理学系,北京100191

出　　处：《临床药物治疗杂志》2014年第4期45-48,共4页Clinical Medication Journal

基　　金：北京市科委首都市民健康项目(z131100004013009)

摘　　要：目的:细胞色素P450是药物及其他外源性物质的主要代谢酶,其亚家族成员之一CYP3A4的基因多态性是导致药物代谢个体差异的主要原因之一。笔者就CYP3A4及其他CYP450酶亚家族基因多态性对镇痛麻醉药品的影响进行讨论,为临床个体化用药提供指导。方法:通过查阅近期国内外文献及资料进行分析。结果与结论镇痛麻醉药品芬太尼、咪哒唑仑、可待因、氯胺酮、曲马多、羟考酮等都会因CYP3A4及其他CYP450酶亚家族基因多态性的存在而在药效和不良反应等方面显现出个体差异性。为提高疗效、避免毒副作用的发生,在临床使用镇痛麻醉药物过程中实行个体化用药十分必要。Objective： The cytochrome P450 enzyme family are the main metabolizing enzymes for many drugs and xenobiotics, referred to as CYP450. Polymorphism of Cytochrome P450 3A4 （CYP3A4）, one of CYP450 sub-family, is one of the main reasons leading to interindividual differences in drugs metabolism. The effect of CYP3A4 and other CYP450 sub-family gene polymorphism of anesthetic and analgesic drugs were discussed in this article in order to provide a guidance for personalized medicine. Methods： This article was conducted via searching recent domestic and abroad literatures. Results and Conclusion： Anesthetic and analgesic drugs, such as fentanyl, midazolam, ketamine, tramadol, codeine and oxycodone, may have different efficacy and adverse reactions in individuals due to polymorphism of CYP3A4 and other CYP450 sub-family. In order to improve the efficacy and avoid toxic and adverse effects of anesthetic and analgesic drugs, it is necessary to implement personalized medicine on clinical use of anesthetic and analgesic drugs.

关 键 词：CYP3A4 基因多态性 麻醉药物 

分 类 号：R971.2[医药卫生—药品]